Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Veracyte ( (VCYT) ) has provided an announcement.
Veracyte‘s stockholders convened for their Annual Meeting, where they elected seven directors to serve until the 2026 annual meeting. Additionally, they ratified Ernst & Young LLP as the independent registered public accounting firm for 2025 and approved the compensation of the company’s named executive officers on a non-binding advisory basis. Stockholders also decided that future advisory votes on executive compensation will occur annually, aligning with the company’s recommendation. Furthermore, the 2023 Plan Amendment received approval.
The most recent analyst rating on (VCYT) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Veracyte stock, see the VCYT Stock Forecast page.
Spark’s Take on VCYT Stock
According to Spark, TipRanks’ AI Analyst, VCYT is a Outperform.
Veracyte’s overall stock score reflects strong financial performance and positive earnings call sentiment, suggesting potential growth. However, technical indicators reveal bearish momentum, and high valuation levels pose a risk. Despite these challenges, Veracyte’s strategic initiatives and robust financials position it well for future opportunities.
To see Spark’s full report on VCYT stock, click here.
More about Veracyte
Average Trading Volume: 1,012,326
Technical Sentiment Signal: Sell
Current Market Cap: $2.09B
Learn more about VCYT stock on TipRanks’ Stock Analysis page.